Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00473577 · ClinicalTrials.gov registry record · Phase 1
Study of the Tolerability, Safety, and Pharmacokinetics of CRA-024781 in Cancer Patients
A Phase 1 study, sponsored by Pharmacyclics.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT00473577 is a Phase 1 study that has completed, run by Pharmacyclics. The registered enrollment target is 40 participants.
The verdict
NCT00473577, a Phase 1 study, has completed, sponsored by Pharmacyclics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
To determine the maximum tolerated dose (MTD) of CRA-024781 IV given by 2-hour intravenous infusions in patients with refractory solid or hematologic malignancies. To evaluate safety and tolerability, pharmacokinetics and pharmacodynamics, and to evaluate bioavailability of CRA-024781 IV when administered in a single oral dose.
Interventions
- DRUG CRA-24781
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2005-08 |
| Est. Completion | 2007-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00473577
The ClinicalTrials.gov registry entry for NCT00473577 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pharmacyclics, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CRA-24781 is the first listed.
NCT00473577 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00473577 about?
NCT00473577 is a clinical study titled "Study of the Tolerability, Safety, and Pharmacokinetics of CRA-024781 in Cancer Patients". To determine the maximum tolerated dose (MTD) of CRA-024781 IV given by 2-hour intravenous infusions in patients with refractory solid or hematologic malignancies. To evaluate safety and tolerability, pharmacokinetics and pharmacodynamics, and to evaluate bioavailability of CRA-024781 IV when admini...
What is the current status of trial NCT00473577?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2005-08. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00473577?
The interventions under investigation include: CRA-24781 (DRUG).
Who is sponsoring clinical trial NCT00473577?
This trial is sponsored by Pharmacyclics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.